Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.

ABSTRACT: The immunologic basis for the potential enhanced HIV-1 acquisition in adenovirus serotype 5 (Ad5)-seropositive individuals who received the Merck recombinant Ad5 HIV-1 vaccine in the STEP study remains unclear. Here we show that baseline Ad5-specific neutralizing antibodies are not correlated with Ad5-specific T lymphocyte responses and that Ad5-seropositive subjects do not develop higher vector-specific cellular immune responses as compared with Ad5-seronegative subjects after vaccination. These findings challenge the hypothesis that activated Ad5-specific T lymphocytes were the cause of the potential enhanced HIV-1 susceptibility in the STEP study.

SUBMITTER: O'Brien KL 

PROVIDER: S-EPMC2756115 | biostudies-literature | 2009 Aug

REPOSITORIES: biostudies-literature